CAR Ts make the move to earlier lines of treatment despite access barriers
Kite reports first-line Yescarta data as companies across the field set their sights on treating patients earlier
Access barriers may still exist, but as evidence of CAR T durability and safety mounts, companies think it’s time to bring the new modality to earlier stages of disease.
CAR T manufacturers and payers are still negotiating access for B cell lymphoma patients without other treatment options, but that hasn’t stopped companies from pressing on into earlier lines of treatment.
With evidence of durability mounting and strategies to mitigate toxicity bringing down the safety risks, CAR T developers are mapping out strategies to reach more patients. One area where they’ve begun to break ground is moving the new modality earlier in the course of treatment.